Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis (NAFT-600)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01289015
Recruitment Status : Completed
First Posted : February 3, 2011
Results First Posted : September 26, 2013
Last Update Posted : September 26, 2013
Information provided by (Responsible Party):
Merz North America, Inc.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.

Condition or disease Intervention/treatment Phase
Tinea Pedis Drug: NAFT-600 ( naftin 2 % gel ) Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 855 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Study Start Date : February 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: NAFT-600 ( naftin 2 % gel) Drug: NAFT-600 ( naftin 2 % gel )
Topical; applied once daily for two weeks
Placebo Comparator: Placebo Drug: Placebo
Topical; applied once daily for two weeks

Primary Outcome Measures :
  1. Complete Cure of Interdigital Tinea Pedis [ Time Frame: Visit 4/ Week 6 ]

    The primary efficacy comparison between NAFT-600 gel and placebo will be based on the percentage of subjects at Week 6 with complete cure of interdigital tinea pedis.

    Complete cure is defined as negative mycology results (dermatophyte culture and KOH) and the absence of erythema, scaling, and pruritus.

Secondary Outcome Measures :
  1. Effective Treatment and Mycological Cure of Interdigital Tinea Pedis at Week 6 [ Time Frame: Visit 4/ Week 6. ]

    Effective treatment of interdigital tinea pedis which is defined as negative KOH and negative dermatophyte culture and erythema, scaling, and pruritus scores of 0 or 1 (corresponding to absent and mild respectively).

    Mycological cure of interdigital tinea pedis which is defined as negative KOH and negative dermatophyte culture.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or non-pregnant females, ≥12 years of age, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test.
  • Presence of interdigital only or both interdigital and moccasin types of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling and mild pruritus) based on signs and symptoms in the affected area(s)).

Exclusion Criteria:

  • Subjects with life-threatening condition (ex. autoimmune deficiency syndrome, cancer,unstable angina or myocardial infarction) within the last 6 months.
  • Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.
  • Subjects with a known hypersensitivity to study drugs or their components.
  • Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
  • Uncontrolled diabetes mellitus.
  • Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
  • Current diagnosis of immunocompromising conditions.
  • Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.
  • Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis or bacterial skin infection.
  • Extremely severe tinea pedis (incapacitating).
  • Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01289015

  Hide Study Locations
United States, Arizona
Associated Foot & Ankle Specialists, LLC
Phoenix, Arizona, United States, 85015
United States, California
Skin Surgery Medical Group, Inc.
San Diego, California, United States, 92117
UCSF Dermatology Research
San Francisco, California, United States, 94115
United States, Connecticut
The Savin Center, PC
New Haven, Connecticut, United States, 06511
United States, Florida
Avail Clinical Research
DeLand, Florida, United States, 32720
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States, 32216
International Dermatology Research, Inc.
Miami, Florida, United States, 33144
Miami Dermatology Research Institute, LLC
N. Miami Beach, Florida, United States, 33162
Radiant Research, Inc.
Pinellas Park, Florida, United States, 33781
United States, Idaho
Northwest Clinical Trials
Boise, Idaho, United States, 83704
United States, Kentucky
Physician Skin Care
Louisville, Kentucky, United States, 40217
United States, Michigan
Michigan Center for Skin Care Research
Clinton Township, Michigan, United States, 48038
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, Minnesota
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432-3133
United States, New York
Skin Search of Rochester, Inc.
Rochester, New York, United States, 14623
United States, North Carolina
Crescent Medical Research
Salisbury, North Carolina, United States, 28144
Wake Forest University Health Sciences
Winston Salem, North Carolina, United States, 27157
United States, Pennsylvania
Paddington Testing Co., Inc.
Philadelphia, Pennsylvania, United States, 19103
United States, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee, United States, 37215
United States, Texas
DermResearch, Inc.
Austin, Texas, United States, 78759
The Center for Skin Research
Houston, Texas, United States, 77056
Endeavor Clinical Trials, PA
San Antonio, Texas, United States, 78229
Puerto Rico
Advanced Medical Concepts, PSC
Cidra, Puerto Rico, 00739
Sponsors and Collaborators
Merz North America, Inc.
Principal Investigator: Lawrence Parish, MD Paddington Testing Co., Inc.

Responsible Party: Merz North America, Inc. Identifier: NCT01289015     History of Changes
Other Study ID Numbers: MRZ 90200/3015/1
First Posted: February 3, 2011    Key Record Dates
Results First Posted: September 26, 2013
Last Update Posted: September 26, 2013
Last Verified: July 2013

Keywords provided by Merz North America, Inc.:
fungal infection
athlete foot

Additional relevant MeSH terms:
Tinea Pedis
Skin Diseases, Infectious
Skin Diseases
Foot Dermatoses
Foot Diseases
Skin Manifestations
Signs and Symptoms